{"disease":{"id":"idh1-mutant-glioma","name":"idh1 mutant glioma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05303519","title":"SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":365,"lead_sponsor_name":"Nuvation Bio Inc.","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}